GlassScriptPhysician profile
Dov Y Shapiro
NPI 1801995634
$44,973.89
in general payments reported to CMS, 2019-2025
31 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $120 · 2021: $1,745 · 2022: $13K · 2023: $14K · 2024: $14K · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $21K · Food and Beverage: $4,496 · Travel and Lodging: $3,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $21,425.00 |
| Food and Beverage | $4,495.99 |
| Travel and Lodging | $3,785.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cepheid | $38,767.93 | 2021-2025 | Genexpert |
| Supernus Pharmaceuticals, INC. | $1,173.84 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $559.04 | 2021-2025 | Azstarys |
| Seqirus USA INC | $530.22 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Ironshore Pharmaceuticals INC. | $461.11 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $427.53 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Merck Sharp & Dohme LLC | $366.32 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Neos Therapeutics, LP | $361.77 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Pfizer INC. | $310.41 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $290.07 | 2020-2022 | |
| Kaleo, INC. | $253.93 | 2019-2024 | Auvi-Q |
| Sanofi Pasteur INC. | $214.01 | 2019-2025 | |
| Vertical Pharmaceuticals, LLC | $194.10 | 2019-2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $155.29 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $143.20 | 2019-2024 | Doc Band |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $90.66 | 2023-2024 | Strensiq, Koselugo |
| Phadia US INC. | $86.91 | 2021-2023 | Immunocap |
| Verrica Pharmaceuticals INC. | $78.42 | 2024-2025 | Ycanth |
| Glaxosmithkline, LLC. | $75.36 | 2021-2022 | |
| Noven Therapeutics, LLC | $71.00 | 2024 | Xelstrym |
| Sobi, INC | $63.63 | 2022-2023 | |
| Shire North American Group INC | $46.04 | 2019 | |
| Adlon Therapeutics L.P. | $44.91 | 2019-2021 | |
| Hologic Sales and Service, LLC | $39.34 | 2019-2021 | |
| Genentech USA, INC. | $38.19 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $29.92 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $27.23 | 2025 | Neffy |
| Biomarin Pharmaceutical INC. | $24.02 | 2024 | Voxzogo 1.2mg |
| Noven Pharmaceuticals, INC. | $20.98 | 2024 | Xelstrym |
| Abbvie INC. | $16.59 | 2019 | |
| Alk-Abello, INC | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dov Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.